Effect of AIV007 by Periocular Administration in Subjects With nAMD or DME

Save

Report Abuse

Description

To determine safety, pharmacokinetics, and duration of effect of periocularly administered AIV007 gel suspension in subjects with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME).

Study Overview

Start Date
March 2, 2023
Completion Date
April 6, 2025
Enrollment
30
Date Posted
January 26, 2023
Accepts Healthy Volunteers?
No
Gender
All

Locations

Full Address
Retina Consultants of Austin
Austin, Texas 78705, United States

Eligibility

Minimum Age (years)
21
Maximum Age (years)
90
Eligibility Criteria
Inclusion Criteria:

General inclusion Criteria:

Male or female subjects aged 21-90 years (inclusive) at screening
BCVA in the study eye at screening and baseline/Day 1: ETDRS letter score ≤ 75 and ≥ 24 (20/32 to 20/330 Snellen equivalent)
Subject must have received treatment within the 24 months before screening with intravitreal (IVT) injections of an anti-VEGF agent with the last anti-VEGF injection in the study eye being at least 6 weeks (42 days) before baseline/Day 1.
Subject has documentation of anti-VEGF responsiveness
Subject must provide written informed consent before any study-related procedures are performed
Clear ocular media and adequate pupil dilation in both eyes to permit good-quality photographic imaging

nAMD subject

The active CNV is confirmed by FA (evidence of leakage)
Residual intraretinal or subretinal fluid based on SD-OCT
CST ≥ 300 µm as assessed by SD-OCT
Total lesion size < 10 disc areas (25.4 mm2)
Absence of geographic atrophy within 200 µm of the fovea
If subretinal hemorrhage is present, it must be < 50% of the total CNV lesion and/or not involve the fovea
If fibrosis is present, it must be <50% of the total lesion area

DME subject

Diagnosis of diabetes mellitus (Type 1 or Type 2)
Subject has clinically significant DME with central involvement (CST≥300 μm by OCT)
The decrease in vision in the study eye was determined by the investigator to be primarily the result of DME

Exclusion Criteria:

Previous treatment for nAMD or DME in the study eye other than standard-of-care anti-VEGF IVT injection, e.g., cell therapy, brachytherapy, gene therapy
Uncontrolled IOP, defined as an IOP > 25 mmHg
Poorly controlled diabetes mellitus defined as hemoglobin A1c (HbA1c) >10% at screening visit
The spherical equivalent for refractive error in the study eye of worse than 8.0 diopters of myopia (before cataract or refractive surgery) per the current prescription
Any history of active bacterial, viral, fungal, or parasitic ocular or periocular infection, or intraocular inflammation in either eye within the 30 days before the screening Visit
History of vitreous hemorrhage within 3 months before screening in the study eye
Uncontrolled systemic disease or any other condition or therapy that would make the participant unsuitable for the study
Participation in any investigational study within 60 days before the screening visit, or planned use of an investigational product or device during the study; any exposure to a prior investigational drug product must be fully washed out (at least 5 half-lives)
History of allergy or hypersensitivity to constituents of the study treatment formulation, topical iodine, ocular antimicrobial solutions, or clinically relevant hypersensitivity to fluorescein

Study Contact Info

Study Contact Name
Darlene Deecher, PhD; Jennifer Wang, PhD
Study Contact Phone

Contact Listings Owner Form

Effect of AIV007 by Periocular Administration in Subjects With nAMD or DME 0 reviews

Write Your Review

There are no reviews yet.

Write Your Review

Your email address will not be published. Required fields are marked *

Other Details

FDA Regulated Drug?
Yes
FDA Regulated Device?
No
NCTid (if applicable)
NCT05698329